Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFHUGC)

Drug Name
SB 269970-A Drug Info
Synonyms
SB-269970 hydrochloride; 261901-57-9; SB 269970 hydrochloride; SB269970 HCl; (R)-3-((2-(2-(4-Methylpiperidin-1-yl)ethyl)pyrrolidin-1-yl)sulfonyl)phenol hydrochloride; SB-269970 (hydrochloride); (R)-3-[2-[2-(4-Methylpiperidin-1-yl)ethyl]pyrrolidine-1-sulfonyl]phenol hydrochloride; SR-01000076135; EU-0101059; SB269970 hydrochloride; C18H29ClN2O3S; MLS002153418; SB 269970 hcl; SCHEMBL2719586; CHEMBL1256844; KS-00000XMZ; CTK8B9470; SB-269970 HCl; MolPort-003-959-592; BCP14529; Tox21_501059; MFCD03788020; ANW-62575; s2849
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
11957684
TTD Drug ID
DMFHUGC

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting 5-HT 7 receptor (HTR7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RP5063 DMKUE8O Schizophrenia 6A20 Phase 2 [2]
JNJ-18038683 DMV1T59 Major depressive disorder 6A70.3 Phase 2 [3]
AVN-101 DMOGFNI Cognitive impairment 6D71 Phase 2 [4]
ATI-9242 DM6GKMU Schizophrenia 6A20 Phase 1 [5]
PMID30124346-Compound-34TABLE4 DM2G3VE Attention deficit hyperactivity disorder 6A05.Z Patented [6]
PMID30124346-Compound-13TABLE4 DMHTJVA Attention deficit hyperactivity disorder 6A05.Z Patented [6]
Carbamide derivative 2 DMW5GI3 N. A. N. A. Patented [7]
4-oxadiazole derivative 1 DMWFHKR N. A. N. A. Patented [7]
SB-269970 DM8WTGA Sleep-wake disorder 7A00-7B2Z Terminated [8]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 7 receptor (HTR7) TTO9X1H 5HT7R_HUMAN Antagonist [1]

References

1 5-HT7 receptors. Curr Drug Targets CNS Neurol Disord. 2004 Feb;3(1):81-90.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Selective pharmacological blockade of the 5-HT7 receptor attenuates light and 8-OH-DPAT induced phase shifts of mouse circadian wheel running activity. Front Behav Neurosci. 2015 Jan 15;8:453.
4 AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders. J Alzheimers Dis. 2016 May 25;53(2):583-620.
5 Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12.
6 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
7 Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
8 [(3)H]-SB-269970--A selective antagonist radioligand for 5-HT(7) receptors. Br J Pharmacol. 2000 May;130(2):409-17.
9 Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.